阿仑膦酸钠（AlendronateSodium）属第三代二膦酸盐类骨吸收抑制剂，1993年在意大利首次上市，1995年9月获美国FDA批准用于治疗骨质疏松症（Osteoporosis）和变形性骨炎（Paget’s骨病）[1]，1997年5月FDA再次批准其预防骨质疏松和预防骨折的扩大适应症[2]，成为第一个被FDA批 Alendronate Sodium, the third generation of bisphosphonate bone resorption inhibitor, was first introduced in Italy in 1993 and approved by the U.S. FDA in September 1995 for the treatment of osteoporosis and deformability Osteitis (Paget’s Osteopathy) [1], the FDA approved again in May 1997 to prevent osteoporosis and prevent the expansion of the indications of fracture [2], becoming the first approved by the FDA